HB 1333 — Drug Control Act; adds certain chemicals to Schedules I, II, IV, and V of Act.
Last action — Acts of Assembly Chapter text (CHAP0062)
-
✓Introduced
-
✓In Committee
-
✓Passed House of Delegates
-
✓Passed Senate
-
✓To Executive
-
6Enacted
This bill has been enacted into law. Introduced January 11, 2024. Enacted.
Signed by Governor Glenn Youngkin (Republican) on March 08, 2024.
Odds of enactment
High chanceBased on the sponsor, cosponsors, and committee posture, this bill has a high chance of becoming law.
Upgrade to see the exact probability and what's driving it.
A statistical estimate from our own model of past outcomes — an insight, not a guarantee. Policymaking is volatile.
Prognosis
-
Enacted
Current position in the legislative process.
-
1 sponsor
1 primary, 0 co-sponsors signed on.
-
Cleared a recorded vote
Passed 5 recorded votes so far.
Based on stage, sponsorship breadth, committee status, recorded votes, and cross-state momentum — a description of the observable signals, not a prediction.
Summary
Drug Control Act; Schedule I; Schedule II; Schedule IV; Schedule V. Adds certain chemicals to Schedules I, II, IV, and V of the Drug Control Act. The Board of Pharmacy has added these substances in an expedited regulatory process. A substance added via this process is removed from the schedule after 18 months unless a general law is enacted adding the substance to the schedule. This bill incorporates HB 1450 and is identical to SB 111.
Bill Text
What changed in the latest version
871 added · 839 removedPlain-language change summary
The recent amendment to HB 1333 updates specific sections of Virginia's Drug Control Act by modifying the language related to controlled substances classified under Schedule I. The main change involves clarifying the terms and removing some repetitive phrasing, which streamlines the definitions of certain opiates and related compounds. This matters because clearer language helps law enforcement and healthcare professionals better understand the legal status of these substances, potentially improving public safety and regulatory enforcement.
SESSION ENROLLED VIRGINIA ACTS OF ASSEMBLY ––-- 2024 SESSION CHAPTER E62 An Act to amend and reenact §§ 54.1-3446, 54.1-3448, 54.1-3452, and 54.1-3454 of the Code of N Virginia, relating to Drug Control Act;
R O [H 1333] Approved LMarch L8, 2024 Be it enacted by the General Assembly of Virginia:
That §§ 54.1-3446, 54.1-3448, 54.1-3452, and 54.1-3454 of the Code of Virginia are amended aEdand reenacted as follows:
D§ The54.1-3446. controlled substances listed in this section are included in Schedule I:
Schedule I.
The controlled substances listed in this section are included in Schedule I:
Any of the following opiates, including their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, unless specifically excepted, whenever the existence of these isomers, esters, ethers andand1-{1-[1-(4-bromophenyl)ethyl]-4-piperidinyl}-1,3-dihydro-2H-benzimidazol-2-one salts(other isname: possible within the specific chemical designation:
1-{1-[1-(4-bromophenyl)ethyl]-4-piperidinyl}-1,3-dihydro-2H-benzimidazol-2-one (other name:
2-methyl AP-23H);AP-237);
11-(4-cinnamyl-2,6-dimethylpiperazin-1-yl)propan-1-one 1-methoxy-3-[4-(2-methoxy-2-phenylethyl)piperazin-1-yl]-1-phenylpropan-2-ol (other name:
AP-238);
1-methoxy-3-[4-(2-methoxy-2-phenylethyl)piperazin-1-yl]-1-phenylpropan-2-ol (other name:
E 2-(4-ethoxybenzyl)-5-nitro-1-[2-(pyrrolidin-1-yl)ethyl]-1H-benzimidazole (other names:
2-methoxy-N-phenyl-N-[1-(2-phenylethyl)-4-piperidinyl]-aceta(other2-methoxy-N-phenyl-N-[1-(2-phenylethyl)-4-piperidinyl]-acetamide (other name:
3,4-dichloro-N-[2-(dimethylamino)cyclohexyl]-N-methyl-benzamide (other name:
U-47700);
AH-7921););AH-7921);
Benzethidine;
Difenoxin;
Etoxeridine;
of 15 Ketobemidone;
of 14 Levophenacylmorphan;
N-[1-[2-(4-methylphenyl)ethyl]piperidin-4-yl]-N-phenylacet(otherN-[1-[2-(4-methylphenyl)ethyl]piperidin-4-yl]-N-phenylacetamide (other name:
N,N-diethyl-2-(2-(4-isopropoxybenzyl)-5-nitro-1H-benzimidazol-1-yl)ethan-1-(otherN,N-diethyl-2-(2-(4-isopropoxybenzyl)-5-nitro-1H-benzimidazol-1-yl)ethan-1-amine (other name:
of 15 Metodesnitazene);
E Protonitazene);
Rof 14 N-phenyl-N-(4-piperidinyl)-propanamide (other name:
Noracymethadol;
O Normethadone;
L Norpipanone;
E N-phenyl-N-[1-(2-phenylethyl)-4-piperidinyl]-butanamide (other name:
D N-phenyl-N-[1-(2-thienyl)ethyl-4-piperidinyl]-propanamide (other name:
thiophene fenPhenadoxone;fentanyl);
Phenadoxone;
H Piritramide;
B Proheptazine;
3 Properidine;
R Racemoramide;
Trimeperidine;
2-methyl-N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]butanamide (name:(other name:
Show all 197 changed lines (157 more)
2-(2,4-dichlorophenyl)-N-[2-(dimethylamino)cyclohexyl]-N-methyl acetamide (other name:
U-48800);
N-(4-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)pentana(otherN-(4-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)pentanamide (other names:
N-(4-fluorophenyl)-N-[1-(2-phenylethyl)piperidin-4-yl]acet(otherN-(4-fluorophenyl)-N-[1-(2-phenylethyl)piperidin-4-yl]acetamide (other name:
4-mN-phenyl-2-methyl-N-[1-(2-phenylethyl)-4-piperidinyl]-propanamide4-methoxybutyrylfentanyl); (other name:
N-phenyl-2-methyl-N-[1-(2-phenylethyl)-4-piperidinyl]-propanamide (other name:
N-phenyl-N-[1-(2-phenylethyl)-4-piperidinyl]-cyclopentanecarbox(otherN-phenyl-N-[1-(2-phenylethyl)-4-piperidinyl]-cyclopentanecarboxamide (other name:
Phenyl fentanyl, Benzoyl fenN-[2-(dimethylamino)cyclohexyl]-N-phenylfuran-2-carboxamidefentanyl); (other name:
N-[2-(dimethylamino)cyclohexyl]-N-phenylfuran-2-carboxamide (other name:
of 15 3,4-dichloro-N-[2-(dimethylamino)cyclohexyl]-N-isopropyl-benzamide (other name:
of 14 Acetyldihydrocodeine;
of 15 Salvinorin A;
E 2,5-DMA);
R 3,4-methylenedioxy-N-ethylamphetamine (also known as N-ethyl-alpha-methyl-3,4 (meN-hydroxy-3,4-methylenedioxyamphetamineA,(methylenedioxy)phenethylamine, N-ethyl MDA, MDE, MDEA);
N-hydroxy-3,4-methylenedioxyamphetamine (some other names:
O N-hydroxy-alpha-methyl-3,4(methylenedioxy)phenethylamine, and N-hydroxy MDA);
L 4-bromo-2,5-dimethoxyamphetamine (some trade or other names:
Lof 14 4-methoxyamphetamine (some trade or other names:
E paramethoxyamphetamine;
N-ethyl-1-phenylcyclohexylamine, D (1-phenylcyclohexyl) ethylamine, N-(1-phenylcyclohexyl) ethylamine, cyclohexamine, PCE);
1-(1-phenylcyclohexyl)-pyrrolidine, PCPy, PHPThiophenePHP); analog of phencyclidine (some other names:
Thiophene analog of phencyclidine (some other names:
H 4-methylmethcathinone (other names:
B 3,4-methylenedioxymethcathinone (other name:
3 Naphthylpyrovalerone (other name:
R 4-methoxymethcathinone (other names:
3,4-methylenedioxyethcathinone (other name:
ethylone);
4-Iodo-2,5-dimethoxyphenethylamine (other name:
2C-I);
name:
2C-I);
25-I, 25IMethoxetamine25I-NBOMe, (other2C-I-NBOMe); names:
Methoxetamine (other names:
(2-aminopropyl)benzofuran (other name:
APB);
of 15 2C-C-NBOMe, 25C-NBOMe, 25C);
of 14 Beta-keto-4-bromo-2,5-dimethoxyphenethylamine (other name:
1-(1,3-benzodioxol-5-yl)-2-(dimethylamino)-1-pentan(other1-(1,3-benzodioxol-5-yl)-2-(dimethylamino)-1-pentanone (other names:
of 15 4-ethyl-2,5-dimethoxy-N-[(2-hydroxyphenyl)methyl]-benzeneethanamine (other name:
E 4-hydroxy-N-ethyl-N-propyltryptamine (other name:
N-Isobutyl Hexedrone, N alpha-isobutylaminohexanphenone);
R 1-(4-methoxyphenyl)-N-methylpropan-2-amine (other names:
para-Methoxymethamphetamine, PMMN-ethyl-1-(3-hydroxyphenyl)cyclohexylaminePMMA); (other name:
N-ethyl-1-(3-hydroxyphenyl)cyclohexylamine (other name:
O N-heptyl-3,4-dimethoxyamphetamine (other name:
L N-hexyl-3,4-dimethoxyamphetamine (other name:
L 4-fluoro-alpha-methylamino-valerophenone (other name:
E N-(1,4-dimethylpentyl)-3,4-dimethoxyamphetamine (other name:
D Alpha-pyrrolidinocyclohexanophenone (other name:
1-(1,3-benzodioxol-5-yl)-2-(cyclohexylamino)butan-1-one4-chloro-alpha-methylaminobutiophenone (other names:name:
4-chloro Buphedrone);
of 14 1-(1,3-benzodioxol-5-yl)-2-(cyclohexylamino)butan-1-one (other names:
H 1-[1-(3-chlorophenyl)cyclohexyl]-piperidine (other names:
3-Chloro Phencyclidine, 3Cl-PCP, B 3-chloro PCP);
3 1-[1-(3-fluorophenyl)cyclohexyl]piperidine (other names:
R 5-methoxy-3,4-methylenedioxyamphetamine, 3-methoxy MDA, MMDA);
N-ethylpentedrone, alp2-(ethylamino)-2-(2-fluorophenyl)-cyclohexanonealpha-ethylaminopentiophenone); (other names:
2-(ethylamino)-2-(2-fluorophenyl)-cyclohexanone (other names:
Alpha-pyrrolidino-2-phenylacetophenone (other name:
alpha-D2PV).
Etizolam;etizolam;Deschloroetizolam;
Etizolam;
Bromonordiazepam);l-1,3-dihydro-1,4-benzodiazepin-2-one7-bromo-5-phenyl-1,3-dihydro-1,4-benzodiazepin-2-one (other names:
Desalkylgidazepam, 7-chloro-5-(2-chlorophenyl)-1-methyl-3H-1,4-benzodiazepin-2-oneBromonordiazepam); (other names:
Diclazepam,7-chloro-5-(2-chlorophenyl)-1-methyl-3H-1,4-benzodiazepin-2-one of(other 15names: 2-Chlorodiazepam);
8-bromo-6-(2-chlorophenyl)-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodia(otherDiclazepam, names:2-Chlorodiazepam);
8-bromo-6-(2-chlorophenyl)-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine(other names:
of 14 N-methyl-1-(thiophen-2-yl)propan-2-amine (other name:
N-(adamantyl)-indole-3-carboxamide with substitution at the nitrogen atom of the indole ring, of 15 whether or not further substituted on the indole ring to any extent, whether or not substituted on the adamantyl ring to any extent;
and E N-(adamantyl)-indazole-3-carboxamide with substitution at a nitrogen atom of the indazole ring, whether or not further substituted on the indazole ring to any extent, whether or not substituted on the adamantyl ring to any extent.
R b.
ADB-5Br-INACA);-amino-3,3-dimethyl-1-oxobutan-2-yl)-1H-indazole-3-carboxamide5-bromo-N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1H-indazole-3-carboxamide (other name:
OADB-5Br-INACA); 5-(1,1-Dimethylheptyl)-2-[3-hydroxycyclohexyl]-phenol (other name:
5-(1,1-Dimethylheptyl)-2-[3-hydroxycyclohexyl]-phenol (other name:
L 5-(1,1-Dimethylhexyl)-2-[3-hydroxycyclohexyl]-phenol (other name:
L 5-(1,1-Dimethylnonyl)-2-[3-hydroxycyclohexyl]-phenol (other name:
E 1-pentyl-3-(1-naphthoyl)indole (other names:
D 1-pentyl-3-(2-methoxyphenylacetyl)indole (other name:
1-[2-(4-morpholinyl)ethyl]-3-(1-naphthoyl)indole (other name:
JWH-200);
H 1-pentyl-3-(2-chlorophenylacetyl)indole (other name:
B 1-pentyl-3-(4-ethyl-1-naphthoyl)indole (other name:
3of 14 1-pentyl-3-(4-chloro-1-naphthoyl)indole (other name:
R 1-((N-methylpiperidin-2-yl)methyl)-3-(1-naphthoyl)indole (other name:
Pravadolinelpi(4-methoxyphenyl)-[2-methyl-1-(2-(4-morpholinyl)ethyl)indol-3-yl]meth(other1-[(N-methylpiperidin-2-yl)methyl]-3-(2-iodobenzoyl)indole (other name:
AM-2233);
Pravadoline (4-methoxyphenyl)-[2-methyl-1-(2-(4-morpholinyl)ethyl)indol-3-yl]methanone (other name:
1-pentyl-3-(1-adamantoyl)indole (other name:
AB-001);
ADB-PINACA);o-3,3-dimethyl-1-oxobutan-2-yl)-1-pentylindazole-3-carboxamideN-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentylindazole-3-carboxamide (other name:
N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)indazole-3-carboxa(otherADB-PINACA); name:
N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)indazole-3-carboxamide (other name:
1-naphthalenyl 1-(5-fluoropentyl)-1H-indole-3-carboxylate (other name:
NM-2201);
of 15 N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-[(4-fluorophenyl)methyl]-1H-indazole-3-carboxamide (other name:
Methyl 2-({1-[(4-fluorophenyl)methyl]-1H-indazole-3-carbonyl}amino)-3-methylbuta(other2-({1-[(4-fluorophenyl)methyl]-1H-indazole-3-carbonyl}amino)-3-methylbutanoate (other names:
N-(adamantan-1-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxam(otherN-(adamantan-1-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide (other names:
N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)indazole-3-carbo(otherN-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)indazole-3-carboxamide (other name:
of 14 Methyl 2-[1-4-fluorobutyl)-1H-indazole-3-carboxamido]-3,3-dimethylbutanoate (other name:
Methyl 2-(1-(cyclohexylmethyl)-1H-indole-3-carboxamido)-3,3-dimethylbutan(other2-(1-(cyclohexylmethyl)-1H-indole-3-carboxamido)-3,3-dimethylbutanoate(other names:
of 15 Ethyl 2-[1-pentyl-1H-indazole-3-carboxamido]-3,3-dimethylbutanoate (other name:
N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-phenethyl-1H-indazole-3-carboxam(otherN-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-phenethyl-1H-indazole-3-carboxamide (other name:
E ADB-PHETINACA);
N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indole-3-ace(otherN-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indole-3-acetami(other names:
N ADB-FUBIATA, AD-18, FUB-ACADB).
R § 54.1-3448.
The controlled substances listed in this section are included in Schedule II:
Opium and opiate, and any salt, compound, derivative, or preparation of opium or opiate, excluding apomorphine, thebaine-derived butorphanol, dextrorphan, nalbuphine, naldemedine, nalmefene, nalExone,naloxone, naltrexone and their respective salts, but including the following:
D Opium extracts;
Powdered opium;
H Ethylmorphine;
B Etorphine hydrochloride;
3 Hydrocodone;
R Metopon;
Oripavine (3-O-demethylthebaine or 6,7,8,14-tetradehydro-4, 5-aMorphine;y-6-methoxy-17-methylmorphinan-3-ol);5-alpha-epoxy-6-methoxy-17-methylmorphinan-3-ol);
Noroxymorphone;Morphine;
of 14 Noroxymorphone;
Coca leaves and any salt, compound, derivative, or preparation of coca leaves, and any salt, compound, derivative, or preparation thereof which is chemically equivalent or identical with any of these substances, but not including decocainized coca leaves or extractions which do not contain cocaine or ecgonine;
Anileridine;;Alphaprodine;
Anileridine;
Metazocine;;Levorphanol;
Metazocine;
of 15 Methadone –– Intermediate, 4-cyano-2-dimethylamino-4, 4-diphenyl butane;
of 14 5.
of 15 Chlordiazepoxide;
E Clonazepam;
N Clotiazepam;
R Cloxazolam;
Delorazepam;;Daridorexant;
ODelorazepam; Diazepam;
LDiazepam; Dichloralphenazone;
Dichloralphenazone;
L Ethchlorvynol;
E Ethinamate;
D Fludiazepam;
Flurazepam;
H Lemborexant;
B Loprazolam;
3 Lorazepam;
R Mebutamate;
Meprobamate;;Methohexital;
Meprobamate;
of 14 Oxazolam;
Petrichloral;
Zaleplon;;Triazolam;
Zaleplon;
Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a stimulant effect on the central nervous system, including its salts, isomers (whether optical, position, or geometric), and salts of specificsuch chemicalisomers designation:tencewhenever the existence of such salts, isomers, and salts of isomers is possible within the Cathinespecific (+)-norpseudoephedrine;chemical designation:
ofCathine 15(+)-norpseudoephedrine; Diethylpropion;
Diethylpropion;
of 14 Not more than 200 milligrams of codeine, or any of its salts, per 100 milliliters or per 100 grams;
of 15 Gabapentin [1-(aminomethyl)cyclohexaneacetic acid];
E Lacosamide [(R)-2-acetoamido-N-benzyl-3-methoxy-propionamide];
NLasmiditan Pregabalin[2,4,6-trifluoro-N-(6-(1-methylpiperidine-4-carbonyl)pyridine-2-yl-benzamide]; [(S)-3-(aminomethyl)-5-methylhexanoic acid].carbonyl)pyridine-2-yl-benzamide];
Pregabalin [(S)-3-(aminomethyl)-5-methylhexanoic acid].
That the provisions of this act may result in a net increase in periods of imprisonment or Rcommitment. necessary appropriation is $0 for periods of imprisonment in state adult correctional facilities and is $0 for periods of commitment to the custody of the Department of Juvenile Justice.
LPursuant Lto E§ D30-19.1:4 Hof 3the RCode of Virginia, the estimated amount of the necessary appropriation is $0 for periods of imprisonment in state adult correctional facilities and is $0 for periods of commitment to the custody of the Department of Juvenile Justice.
Show all 197 changed rows (157 more)
View plain text versions (4)
- CHAP0062 View text Current pdf March 08, 2024
- HB1333ER View text pdf February 22, 2024
- Committee Substitute Committee substitute printed 24106671D-H1 pdf January 30, 2024
- Presented and ordered printed 24104366D View text pdf January 11, 2024
Action History
-
Acts of Assembly Chapter text (CHAP0062)
-
Approved by Governor-Chapter 62 (effective 7/1/24)
-
Governor's Action Deadline 11:59 p.m., March 8, 2024
-
Enrolled Bill communicated to Governor on March 1, 2024
-
Signed by President
-
Signed by Speaker
-
Impact statement from DPB (HB1333ER)
-
Bill text as passed House and Senate (HB1333ER)
-
Enrolled
-
Passed Senate (39-Y 0-N)
-
Read third time
-
Constitutional reading dispensed (38-Y 0-N)
-
Reported from Education and Health (13-Y 0-N)
-
Referred to Committee on Education and Health
-
Constitutional reading dispensed
-
VOTE: Block Vote Passage (98-Y 0-N)
-
Read third time and passed House BLOCK VOTE (98-Y 0-N)
-
Engrossed by House - committee substitute HB1333H1
-
Committee substitute agreed to 24106671D-H1
-
Read second time
-
Read first time
-
Impact statement from DPB (HB1333H1)
-
Incorporates HB1450 (Thomas)
-
Committee substitute printed 24106671D-H1
-
Reported from Health and Human Services with substitute (22-Y 0-N)
-
Impact statement from DPB (HB1333)
-
Impact statement from VCSC (HB1333)
-
Referred to Committee on Health and Human Services
-
Presented and ordered printed 24104366D
Sponsors
- Jr. H. Otto Wachsmann · Primary
Sponsorship breakdown
Export CSV (upgrade) →1 sponsors · 0 co-sponsors · 147 not signed on
Sponsors (1)
Co-sponsors (0)
None.
Not signed on (147)
147 members have not signed on to this bill.
Show all 147 →"Not signed on" means a member has not sponsored or co-sponsored this bill — it does not imply opposition. Members flagged Voted No have a recorded No vote on this bill.
Votes
| Party | Yea | Nay | Present | Not Voting |
|---|---|---|---|---|
| Unaffiliated | 39 | 0 | 0 | 1 |
| Total | 39 | 0 | 0 | 1 |
| % of votes cast | 98% | 0% | 0% | 3% |
How each member voted (40)
| Member | Party | Vote |
|---|---|---|
| Aaron R. Rouse | — | Yea |
| Angelia Williams Graves | — | Yea |
| Barbara A. Favola | — | Yea |
| Bill DeSteph | — | Yea |
| Bryce E. Reeves | — | Yea |
| Carroll Foy, Jennifer D. | — | Yea |
| Christie New Craig | — | Yea |
| Christopher T. Head | — | Yea |
| Danica A. Roem | — | Yea |
| David R. Suetterlein | — | Yea |
| David W. Marsden | — | Yea |
| Ebbin, Adam P. | — | Yea |
| Emily M. Jordan | — | Yea |
| Glen H. Sturtevant, Jr. | — | Yea |
| Hashmi, Ghazala F. | — | Yea |
| J.D. "Danny" Diggs | — | Yea |
| Jennifer B. Boysko | — | Yea |
| Jeremy S. McPike | — | Yea |
| L. Louise Lucas | — | Yea |
| Lamont Bagby | — | Yea |
| Lashrecse D. Aird | — | Yea |
| Mamie E. Locke | — | Yea |
| Mark D. Obenshain | — | Yea |
| Mark J. Peake | — | Yea |
| McGuire, John J., III | — | Yea |
| R. Creigh Deeds | — | Yea |
| Richard H. Stuart | — | Not Voting |
| Russet Perry | — | Yea |
| Ryan T. McDougle | — | Yea |
| Saddam Azlan Salim | — | Yea |
| Schuyler T. VanValkenburg | — | Yea |
| Scott A. Surovell | — | Yea |
| Stella G. Pekarsky | — | Yea |
| Subramanyam, Suhas | — | Yea |
| T. Travis Hackworth | — | Yea |
| Tammy Brankley Mulchi | — | Yea |
| Tara A. Durant | — | Yea |
| Timmy French | — | Yea |
| Todd E. Pillion | — | Yea |
| William M. Stanley, Jr. | — | Yea |
| Party | Yea | Nay | Present | Not Voting |
|---|---|---|---|---|
| Unaffiliated | 38 | 0 | 0 | 2 |
| Total | 38 | 0 | 0 | 2 |
| % of votes cast | 95% | 0% | 0% | 5% |
How each member voted (40)
| Member | Party | Vote |
|---|---|---|
| Aaron R. Rouse | — | Yea |
| Angelia Williams Graves | — | Yea |
| Barbara A. Favola | — | Yea |
| Bill DeSteph | — | Yea |
| Bryce E. Reeves | — | Yea |
| Carroll Foy, Jennifer D. | — | Yea |
| Christie New Craig | — | Yea |
| Christopher T. Head | — | Yea |
| Danica A. Roem | — | Yea |
| David R. Suetterlein | — | Yea |
| David W. Marsden | — | Yea |
| Ebbin, Adam P. | — | Yea |
| Emily M. Jordan | — | Yea |
| Glen H. Sturtevant, Jr. | — | Yea |
| Hashmi, Ghazala F. | — | Not Voting |
| J.D. "Danny" Diggs | — | Yea |
| Jennifer B. Boysko | — | Yea |
| Jeremy S. McPike | — | Yea |
| L. Louise Lucas | — | Yea |
| Lamont Bagby | — | Yea |
| Lashrecse D. Aird | — | Yea |
| Mamie E. Locke | — | Yea |
| Mark D. Obenshain | — | Yea |
| Mark J. Peake | — | Yea |
| McGuire, John J., III | — | Yea |
| R. Creigh Deeds | — | Yea |
| Richard H. Stuart | — | Yea |
| Russet Perry | — | Yea |
| Ryan T. McDougle | — | Yea |
| Saddam Azlan Salim | — | Yea |
| Schuyler T. VanValkenburg | — | Yea |
| Scott A. Surovell | — | Yea |
| Stella G. Pekarsky | — | Yea |
| Subramanyam, Suhas | — | Yea |
| T. Travis Hackworth | — | Yea |
| Tammy Brankley Mulchi | — | Yea |
| Tara A. Durant | — | Yea |
| Timmy French | — | Not Voting |
| Todd E. Pillion | — | Yea |
| William M. Stanley, Jr. | — | Yea |
| Party | Yea | Nay | Present | Not Voting |
|---|---|---|---|---|
| Unaffiliated | 13 | 0 | 0 | 2 |
| Total | 13 | 0 | 0 | 2 |
| % of votes cast | 87% | 0% | 0% | 13% |
How each member voted (15)
| Member | Party | Vote |
|---|---|---|
| Barbara A. Favola | — | Not Voting |
| Christie New Craig | — | Yea |
| Christopher T. Head | — | Yea |
| David R. Suetterlein | — | Yea |
| Hashmi, Ghazala F. | — | Yea |
| Jennifer B. Boysko | — | Not Voting |
| L. Louise Lucas | — | Yea |
| Lamont Bagby | — | Yea |
| Lashrecse D. Aird | — | Yea |
| Mamie E. Locke | — | Yea |
| Mark J. Peake | — | Yea |
| Schuyler T. VanValkenburg | — | Yea |
| Stella G. Pekarsky | — | Yea |
| Tara A. Durant | — | Yea |
| Todd E. Pillion | — | Yea |
| Party | Yea | Nay | Present | Not Voting |
|---|---|---|---|---|
| Unaffiliated | 97 | 0 | 0 | 2 |
| Total | 97 | 0 | 0 | 2 |
| % of votes cast | 98% | 0% | 0% | 2% |
How each member voted (99)
| Party | Yea | Nay | Present | Not Voting |
|---|---|---|---|---|
| Unaffiliated | 22 | 0 | 0 | 0 |
| Total | 22 | 0 | 0 | 0 |
| % of votes cast | 100% | 0% | 0% | 0% |
How each member voted (22)
| Member | Party | Vote |
|---|---|---|
| C.E. Cliff Hayes, Jr. | — | Yea |
| Charniele L. Herring | — | Yea |
| Debra D. Gardner | — | Yea |
| Ennis, N. Baxter | — | Yea |
| H. Otto Wachsmann, Jr. | — | Yea |
| Higgins, Geary | — | Yea |
| Irene Shin | — | Yea |
| Joshua G. Cole | — | Yea |
| Kannan Srinivasan | — | Yea |
| Kathy K.L. Tran | — | Yea |
| M. Keith Hodges | — | Yea |
| Marcia S. "Cia" Price | — | Yea |
| Mike A. Cherry | — | Yea |
| Orrock, Robert D., Sr. | — | Yea |
| Owen, David | — | Yea |
| Patrick A. Hope | — | Yea |
| Phillip A. Scott | — | Yea |
| Rodney T. Willett | — | Yea |
| Rozia A. Henson, Jr. | — | Yea |
| Sickles, Mark D. | — | Yea |
| Taylor, Kim A. | — | Yea |
| Wendell S. Walker | — | Yea |
Subjects
Frequently asked questions
- What does HB 1333 do?
- Drug Control Act; Schedule I; Schedule II; Schedule IV; Schedule V. Adds certain chemicals to Schedules I, II, IV, and V of the Drug Control Act. The Board of Pharmacy has added these substances in an expedited regulatory process. A substance added via this process is removed from the schedule after 18 months unless a general law is enacted adding the substance to the schedule. This bill incorporates HB 1450 and is identical to SB 111.
- Who sponsors HB 1333?
- HB 1333 is sponsored by H. Otto Wachsmann, Jr..
- What is the current status of HB 1333?
- This bill has been enacted into law. Introduced January 11, 2024. Enacted.
- Where can I track HB 1333?
- Track HB 1333 free on One Click Politics — get push/email alerts when it moves.
Make your voice heard on HB 1333
Find the representatives who decide this bill and tell them where you stand — for yourself, or mobilize your whole list in one click with One Click Politics advocacy software.
Stay ahead of HB 1333
Last checked for changes 3 months ago · updated continuously
One Click Politics tracks every bill in Congress and all 50 states.
Track this bill →